1887

Journal of General Virology header logo

Volume 80, Issue 12

Human papillomavirus type 16 E6 variants in cervical carcinoma: relationship to host genetic factors and clinical parameters Free

Abstract

Infection with human papillomavirus type 16 (HPV-16) confers a high risk for the development of cervical neoplasia. Variants of this virus may interact differentially with host genetic factors, possibly altering the disease course. Thus, HPV-16 E6 variants may differ in their ability to degrade p53 whereas the polymorphic p53 alleles may provide more or less susceptible substrates for the viral oncogene product. Also, E6 variants may differ in immunogenicity by generating different peptides for presentation by polymorphic HLA molecules to specific T cells. This study examines HPV-16 E6 sequence variation in cervical carcinomas from the UK and its relationship to polymorphism of HLA and p53 and to clinical parameters. Sequence analysis of the HPV-16 E6 ORF from 77 tumour biopsies detected the viral prototype sequence in 38% of cases. The most common variation detected was a T to G transition at base pair 350, resulting in an amino acid change from a leucine to a valine. Overall, the frequencies of 350T and 350G sequences were similar (49·4% and 50·6% respectively). Other mutations of lower frequencies were detected together with and independently of 350G. HPV-16 E6 sequence variation at base pair 350 did not correlate with HLA genotype or clinical outcome. There was no difference in the distribution of p53 proline and arginine alleles between HPV-16-positive cervical carcinoma patients and local controls, and no influence on clinical outcome; however, there was a trend for an increased frequency of p53 arginine homozygotes among the 350T carcinoma patients.

  • Received:
  • Accepted:
  • Published Online:
© Microbiology Society
Loading

Article metrics loading...

/content/journal/jgv/10.1099/0022-1317-80-12-3233
1999-12-01
2024-04-25
Loading full text...

Full text loading...

/deliver/fulltext/jgv/80/12/0803233.html?itemId=/content/journal/jgv/10.1099/0022-1317-80-12-3233&mimeType=html&fmt=ahah

References

  1. Bontkes H. J., van Duin M., De Gruijl T. D., Duggan-Keen M. F., Walboomers J. M. M., Stukart M. J., Verhiejen R. H. M., Helmerhorst T. J. M., Meijer C. J. L. M., Scheper R. J., Stevens F. R. A., Dyer P. A., Sinnott P., Stern P. L. 1998; HPV 16 infection and progression of cervical intraepithelial neoplasia: analysis of HLA polymorphism and HPV 16 E6 sequence variants. International Journal of Cancer 78:166–171
     [Google Scholar]
  2. Borysiewicz L. K., Fiander A., Nimako M., Man S., Wilkinson G. W. G., Westmorland D., Evans A. S., Adams M., Stacey S. N., Boursall M. E. G., Rutherford E., Hickling J. K., Inglis S. C. 1996; A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet 347:1523–1527
     [Google Scholar]
  3. Bosch F. X., Munoz N., deSanjose S. 1997; Human papillomavirus and other risk factors for cervical cancer. Biomedicine & Pharmacotherapy 51:268–275
     [Google Scholar]
  4. Cheng G., Icenogle J. P., Kirnbauer R., Hubbert N. L., St Louis M. E., Han C., Svare E. I., Kjaer S. K., Lowy D. R., Schiller J. T. 1995; Divergent human papillomavirus type 16 variants are serologically cross-reactive. Journal of Infectious Diseases 172:1584–1587
     [Google Scholar]
  5. Duggan-Keen M. F., Keating P. J., Stevens F. R. A., Sinnott P., Snijders P. J. F., Walboomers J. M. M., Davidson S., Hunter R. D., Dyer P. A., Stern P. L. 1996; Immunogenetic factors in HPV-associated cervical cancer: influence on disease progression. European Journal of Immunogenetics 23:275–284
     [Google Scholar]
  6. Duggan-Keen M., Brown M., Stacey S., Stern P. 1998; Papillomavirus vaccines. Frontiers in Bioscience 3:1192–1208
     [Google Scholar]
  7. Ellis J. R. M., Keating P. J., Baird J., Hounsell E. F., Renouf D. V., Rowe M., Hopkins D., Duggan-Keen M. F., Bartholomew J., Young L. S., Stern P. L. 1995; The association of an HPV-16 oncogene variant with HLA-B7 has implications for vaccine design in cervical cancer. Nature Medicine 1:464–470
     [Google Scholar]
  8. Ellis J. R. M., Etherington I., Galloway D., Luesley D., Young L. S. 1997; Antibody responses to HPV16 virus-like particles in women with cervical intraepithelial neoplasia infected with a variant HPV16. Lancet 349:1069–1070
     [Google Scholar]
  9. Eriksson A., Herron J. R., Yamada T., Wheeler C. M. 1999; Human papillomavirus type 16 variant lineages characterized by nucleotide sequence analysis of the E5 coding segment and the E2 hinge region. Journal of General Virology 80:595–600
     [Google Scholar]
  10. Etherington I., Ellis J., Luesley D., Moffitt D., Young L. 1999; Histologic and immunologic associations of an HPV16 variant in LoSIL smears. Gynecologic Oncology 72:56–59
     [Google Scholar]
  11. Helland A., Langerod A., Johnsen H., Olsen A., Skovlund E., Borresen-Dale A.-L. 1998; p53 polymorphism and risk of cervical cancer. Nature 396:530–531
     [Google Scholar]
  12. Hilders C. G. J. M., Munoz I. M., Nooyen Y., Fleuren G. J. 1995; Altered HLA expression by metastatic cervical-carcinoma cells as a factor in impaired immune surveillance. Gynaecologic Oncology 57:366–375
     [Google Scholar]
  13. Hildesheim A., Schiffman M., Brinton L., Fraumeni J., Herrero R., Bratti M., Schwartz P., Mortell R., Barnes W., Greenberg M., McGowan L., Scott D., Martin M., Herrera J., Carrington M. 1998a; p53 polymorphism and risk of cervical cancer. Nature 396:532
     [Google Scholar]
  14. Hildesheim A., Schiffman M., Scott D. R., Marti D., Kissner T., Sherman M. E., Glass A. G., Manos M. M., Lorincz A. T., Kurman R. J., Buckland J., Rush B. B., Carrington M. 1998b; Human leukocyte antigen class I/II alleles and development of human papillomavirus-related cervical neoplasia: results from a case-control study conducted in the United States. Cancer Epidemiology, Biomarkers and Prevention 7:E1035–1041
     [Google Scholar]
  15. Ho L., Chan S. Y., Burk R. D., Das B. C., Fujinaga K., Icenogle J. P., Kahn T., Kiviat N., Lancaster W., Mavromara-Nazos P. and others 1993; The genetic drift of human papillomavirus type 16 is a means of reconstructing prehistoric viral spread and the movement of ancient human populations. Journal of Virology 67:6413–6423
     [Google Scholar]
  16. Honma S., Tsukada S., Honda S., Nakamura M., Takakuwa K., Maruhashi T., Kodama S., Kanazawa K., Takahashi T., Tanaka K. 1994; Biological–clinical significance of selective loss of HLA class I allelic product expression in squamous cell carcinoma of the uterine cervix. International Journal of Cancer 57:650–655
     [Google Scholar]
  17. Jin X., Wu X., Roth J. A., Amos C. I., King T. M., Branch C., Honn S. E., Spitz M. R. 1995; Higher lung cancer risk for younger African–Americans with the Pro/Pro p53 genotype. Carcinogenesis 16:2205–2208
     [Google Scholar]
  18. Josefsson A., Magnussin P., Ylitalo N., Quarforth-Tubbin P., Ponten J., Adami H., Gyllensten U. 1998; p53 polymorphism and risk of cervical cancer. Nature 396:531
     [Google Scholar]
  19. Kawajiri K., Nakachi K., Imai K., Watanabe J., Hayashi S. 1993; Germ line polymorphisms of p53 and CYP1A1 genes involved in human lung cancer. Carcinogenesis 14:1085–1089
     [Google Scholar]
  20. Keating P. J., Cromme F. V., Duggan-Keen M., Snijders P. J. F., Walboomers J. M. M., Hunter R. D., Dyer P. A., Stern P. L. 1995; Frequency of down-regulation of individual HLA-A and -B alleles in cervical carcinomas in relation to TAP-1 expression. British Journal of Cancer 72:405–411
     [Google Scholar]
  21. Londesborough P., Ho L., Terry G., Cuzick J., Wheeler C., Singer A. 1996; Human papillomavirus genotype as a predictor of persistence and development of high grade lesions in women with minor cervical abnormalities. International Journal of Cancer 69:364–368
     [Google Scholar]
  22. Lowy D. R., Schiller J. T. 1999; Papillomaviruses: prophylactic vaccine prospects. Biochimica et Biophysica Acta 1423M1–8
     [Google Scholar]
  23. Martin S., Dyer P. 1994; The definition of HLA specificities by cytotoxicity. Transplant Immunology 12:108–111
     [Google Scholar]
  24. Minaguchi T., Kanamori Y., Matsushima M., Yoshikawa H., Taketani Y., Nakamura Y. 1998; No evidence of correlation between polymorphism at codon 72 of p53 and risk of cervical cancer in Japanese patients with human papillomavirus 16/18 infection. Cancer Research 58:4585–4586
     [Google Scholar]
  25. Murata M., Tagawa M., Kimura H., Kakisawa K., Shirasawa H., Fujisawa T. 1998; Correlation of the mutation of p53 gene and the polymorphism at codon 72 in smoking-related non-small cell lung cancer patients. International Journal of Oncology 12:577–581
     [Google Scholar]
  26. Myers G., Bernard H., Delius H., Favre M., Icenogle J., van Ranst M., Wheeler C. 1995 Human Papillomaviruses . A Compilation and Analysis of Nucleic Acid and Amino Acid Sequences Los Alamos: Los Alamos National Laboratory;
     [Google Scholar]
  27. Nindl I., Rindfleisch K., Lotz B., Schneider A., Durst M. 1999; Uniform distribution of HPV E6 and E7 variants in patients with normal histology, cervical intraepithelial neoplasia and cervical cancer. International Journal of Cancer 82:203–207
     [Google Scholar]
  28. Parker K. C., Bednarek M. A., Coligan J. E. 1994; Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. Journal of Immunology 152:163–175
     [Google Scholar]
  29. Rosenthal A. N., Ryan A., Al-Jehani R. M., Storey A., Harwood C. A., Jacobs I. J. 1998; p53 codon 72 polymorphism and risk of cervical cancer in UK. Lancet 352:871–872
     [Google Scholar]
  30. Sjalander A., Birgander R., Hallmans G., Cajander S., Lenner P., Athlin L., Beckman G., Beckman L. 1996; p53 polymorphisms and haplotypes in breast cancer. Carcinogenesis 17:1313–1316
     [Google Scholar]
  31. Snijders P. J. F., Van den Brule A. J. C., Schrijnemakers H. F. J., Snow G., Meijer C. J. L. M., Walboomers J. M. M. 1990; The use of general primers in the polymerase chain reaction permits the detection of a broad spectrum of human papillomavirus genotypes. Journal of General Virology 71:173–181
     [Google Scholar]
  32. Stoppler M. C., Ching K., Stoppler H., Clancy K., Schlegel R., Icenogle J. 1996; Natural variants of the human papillomavirus type 16 E6 protein differ in their abilities to alter keratinocyte differentiation and to induce p53 degradation. Journal of Virology 70:6987–6993
     [Google Scholar]
  33. Storey A., Thomas M., Kalita A., Harwood C., Gardiol D., Mantovani F., Breuer J., Leigh I. M., Matlashewski G., Banks L. 1998; Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature 235:229–234
     [Google Scholar]
  34. Thomas M., Kalita A., Labrecque S., Pim D., Banks L., Matlashewski G. 1999; Two polymorphic variants of wild-type p53 differ biochemically and biologically. Molecular and Cellular Biology 19:1092–1100
     [Google Scholar]
  35. Tommasino M. editor 1997; Papillomaviruses in Human Cancer: The Role of E6 and E7 Oncoproteins. Molecular Biology Intelligence Unit series Austin, Texas: R. G. Landes;
     [Google Scholar]
  36. Van den Brule A. J. C., Meijer C. J. L. M., Bakels V., Kenemans P., Walboomers J. M. M. 1990; Rapid human papillomavirus detection in cervical scrapes by combined general primers mediated and type specific polymerase chain reaction. Journal of Clinical Microbiology 28:2739–2743
     [Google Scholar]
  37. Walboomers J. M. M., Jacobs M. V., van Oostveen J. W., van den Brule A. J. C., Snijders P. J. F., Meijer C. J. L. M. 1997; Detection of human papillomavirus infections and possible clinical implications. In Human Papillomavirus Infections in Dermatovenereology pp. 341–364 Edited by Gross G, von Krogh G. . London, Tokyo & New York: CRC Press;
     [Google Scholar]
  38. Xi L. F., Koutsky L. A., Galloway D. A., Kuypers J., Hughes J. P., Wheeler C. M., Holmes K. K., Kiviat N. B. 1997; Genomic variation of human papillomavirus type 16 and risk for high grade cervical intraepithelial neoplasia. Journal of the National Cancer Institute 89:796–802
     [Google Scholar]
  39. Yamada T., Wheeler C. M., Halpern A. L., Stewart A. M., Hildesheim A., Jenison S. A. 1995; Human papillomavirus type 16 variant lineages in United States populations characterized by nucleotide sequence analysis of the E6, L2 and L1 coding segments. Journal of Virology 69:7743–7753
     [Google Scholar]
  40. Yamada T., Manos M. M., Peto J., Greer C. E., Munoz N., Bosch F. X., Wheeler C. M. 1997; Human papillomavirus type 16 sequence variation in cervical cancers: a worldwide perspective. J ournal of Virology 71:2463–2472
     [Google Scholar]
  41. Zehbe I., Voglino G., Delius H., Wilander E., Tommasino M. 1998a; Risk of cervical cancer and geographical variations of human papillomavirus 16 E6 polymorphisms. Lancet 352:1441–1442
     [Google Scholar]
  42. Zehbe I., Wilander E., Delius H., Tommasino M. 1998b; Human papillomavirus 16 E6 variants are more prevalent in invasive cervical carcinoma then the prototype. Cancer Research 58:829–833
     [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/0022-1317-80-12-3233
Loading
Human papillomavirus type 16 E6 variants in cervical carcinoma: relationship to host genetic factors and clinical parameters
J. Gen. Virol. 80, 3233 (1999); https://doi.org/10.1099/0022-1317-80-12-3233
/content/journal/jgv/10.1099/0022-1317-80-12-3233
/content/journal/jgv/10.1099/0022-1317-80-12-3233
Loading

Data & Media loading...

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error